Navigation Links
Aflac and the American Association for Cancer Research Unite to Issue Inaugural Aflac Career Development Award for Childhood Cancer Research
Date:4/29/2008

s principal activities include the publication of five leading peer-reviewed scientific journals (Cancer Research, Clinical Cancer Research, Molecular Cancer Research, Cancer Epidemiology, Biomarkers & Prevention and Molecular Cancer Therapeutics).

About Dr. Charles Grenfell Mullighan

Dr. Charles Grenfell Mullighan, a native of South Australia, is a hematologist and hematopathologist pursuing research in the molecular biology of acute leukemia. He completed his hematology fellowship in Australia in January 2004 and has served as a Physician Scientist Postdoctoral Fellow in the laboratory of Dr. James Downing, Department of Pathology, St. Jude Children's Research Hospital.

(Logo: http://www.newscom.com/cgi-bin/prnh/20041202/CLTH019LOGO )

Media Contact: Analyst and Investment Contact:

Jon A. Sullivan Kenneth S. Janke Jr.

Aflac Incorporated Aflac Incorporated

706.763.4813 1.800.235.2667, Option 3;

jsullivan@aflac.com Fax: 706.324.6330

kjanke@aflac.com


'/>"/>
SOURCE Alfac Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Aflac Honored with Corporate Citizenship Award
2. American Oriental Bioengineering to Report First Quarter 2008 Financial Results
3. FASgen, Inc. Presents Ovarian Cancer Efficacy and Toxicology Data to the American Association for Cancer Research
4. Telik Presents Preclinical Data at 99th Annual Meeting of the American Association for Cancer Research
5. SPO Medical Retains American Capital Ventures for Investor Relations Services
6. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the Annual Meeting of the American Association for Cancer Research (AACR); Scientific Advisory Board Chairman Tyler Jacks Named President-elect
7. Medarex Reports Phase 1/2 Clinical Data of MDX-060 in Lymphoma at American Association for Cancer Research Meeting
8. American Oriental Bioengineering and China Aoxing Pharmaceutical Enter Into Strategic Alliance
9. Paloma Pharmaceuticals to Present at the American Association for Cancer Research
10. Bionovo to Present Recent Findings of BN107 and BN108, Its Anticancer Agents, at the American Association of Cancer Research
11. Peregrine Pharmaceuticals Announces Four Upcoming Presentations at the American Association for Cancer Research 2008 Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)...  Pharmacyclics, Inc. (NASDAQ: PCYC ) ... newly developed Bruton,s tyrosine kinase (BTK) inhibitor for ... results of these preclinical evaluations have been communicated ... feedback received from the Agency is supportive of ... preclinical work is required to begin a Phase ...
(Date:2/27/2015)... Australia , Feb. 27, 2015 Bionomics ... from the DisrupTOR-1 trial of BNC105 in patients with ... in Orlando, Florida . The data ... of the City of Hope Comprehensive Cancer Center in ... The new data identifies Ferritin and ...
(Date:2/27/2015)... 2015   PureTech , a science and technology ... products and technologies in the healthcare sector, announced today ... and Member of the Board of Directors of Sanofi, ... has been a pleasure to know Chris for many ... be working together more closely now," said Dr. ...
(Date:2/26/2015)... Synageva BioPharma Corp. (NASDAQ: GEVA ... rare disorders, today reported 2014 full year financial ... and financial guidance.  Synageva,s management team will host ... to review the financial results and provide a ... by telephone, please dial (877) 445-4603 for U.S. ...
Breaking Biology Technology:Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 2New BNC105 Biomarker Data to be Presented at US Cancer Conference 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 4New BNC105 Biomarker Data to be Presented at US Cancer Conference 5Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 2Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 3Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 4Synageva BioPharma Reports 2014 Full Year Financial Results 2Synageva BioPharma Reports 2014 Full Year Financial Results 3Synageva BioPharma Reports 2014 Full Year Financial Results 4Synageva BioPharma Reports 2014 Full Year Financial Results 5Synageva BioPharma Reports 2014 Full Year Financial Results 6Synageva BioPharma Reports 2014 Full Year Financial Results 7Synageva BioPharma Reports 2014 Full Year Financial Results 8Synageva BioPharma Reports 2014 Full Year Financial Results 9
... Kosan Biosciences,Incorporated (Nasdaq: KOSN ) announced today ... present at the Leerink Swann,Solid Tumors Roundtable Conference ... on,Friday, May 9, 2008 at 11:10 a.m. EDT. ... through http://www.wsw.com/webcast/leerink15/kosn/ ., Interested parties may ...
... N.C., May 6 There are a lot of ... An organization,s,sales force must be involved with many of ... any successful re-launch effort,according to a study by benchmarking ... a sales force? Half of the companies that,participated in ...
... May 6 , WHAT: ABC,s Dancing with the Stars champion Drew Lachey ... a world leader in diabetes care, to ... diabetes awareness, Dancin, to Change Diabetes. The contest ... that help them stay active and healthy., ...
Cached Biology Technology:Kosan Biosciences to Present at the Leerink Swann Solid Tumors Roundtable Conference 2Invigorated Sales Force Key to a Successful Re-Launch 2Dancing With the Stars' Drew Lachey and Novo Nordisk Launch Dancin' to Change Diabetes National Video Contest 2
(Date:2/5/2015)... , Feb. 3, 2015 Despite ... demand from industries such as consumer electronics, automotive, ... for surface mount technology (SMT) screen printers. Innovations ... automatic control will push the adoption curve up. ... remain steady as glue dispensers are indispensable in ...
(Date:1/22/2015)... Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ON), is pleased to inform ... State of Washington,s Department of Licensing, in the ... issuance system for driver,s licenses and identification cards to its ... development will start in January 2015, with enrollment and card ...
(Date:1/22/2015)... 13, 2015  Today, FreeWavz ( www.FreeWavz.com ), the ... campaign on Fundable, https://www.fundable.com/freewavz . FreeWavz will ... capacity to meet customer demand. Logo ... http://photos.prnewswire.com/prnh/20150113/168790 Invented by Dr. ...
Breaking Biology News(10 mins):End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 2End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 3Valid USA Signs Contract For Washington Driver's License Issuance 2FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2
... attention. But a study led by McGill researcher Sarah Kimmins ... equally important role in the health of their offspring. It ... diets and of food insecurity. The research focused on ... range of green leafy vegetables, cereals, fruit and meats. It ...
... SAN FRANCISCO, Calif. , Dec. 10, 2013 ... today announced preliminary results of an ongoing multi-center ... (mAb), which the company is developing as a ... disease or who were unfit for chemotherapy have ...
... Whitesides, Ph.D., and David Edwards, Ph.D., have been named ... joining 141 other innovators elected this year. ... to academic inventors who have demonstrated a prolific spirit ... tangible impact on quality of life, economic development, and ...
Cached Biology News:You are what your father eats 2KaloBios Announces Preliminary Phase 1 Results in Advanced Hematologic Malignancies with KB004, an Anti-EphA3 Monoclonal Antibody 2KaloBios Announces Preliminary Phase 1 Results in Advanced Hematologic Malignancies with KB004, an Anti-EphA3 Monoclonal Antibody 3KaloBios Announces Preliminary Phase 1 Results in Advanced Hematologic Malignancies with KB004, an Anti-EphA3 Monoclonal Antibody 4KaloBios Announces Preliminary Phase 1 Results in Advanced Hematologic Malignancies with KB004, an Anti-EphA3 Monoclonal Antibody 5Wyss Institute at Harvard University announces election of 2 faculty to Natl Academy of Inventors 2Wyss Institute at Harvard University announces election of 2 faculty to Natl Academy of Inventors 3
Immunogen: Tissue / cell preparation. (Murine EHS laminin preparation) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Human/Mouse APLP-1 MAb (Clone 354020) ENTREZ GeneID: 333...
Mouse monoclonal [4i97] to HLA Class 1 A25 ( Abpromise for all tested applications). Antigen: Full length protein (Human): HLA Class 1 Antigen-A25. Swiss Protein ID: P18462...
... choice of Printing Surface (3 glass slides coated with ... 1 silicon wafer coated with 1000 Angstroms of Gold ... and PDMS Stamps (3 PDMS micropatterned stamps with series ... x 10 mm or 200 um x 10 mm ...
Biology Products: